Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study.

BMC Nephrol · 2024 · PMC10895744 · PMID 38408970

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Also, a decreasing trend in the amount of blood transfusion within 48 h after the start of CKRT was observed as nafamostat mesylate increased.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.